Strides Pharma Science Ltd

Strides Pharma Science experienced a notable rebound on February 13, 2025, reversing a three-day decline with a significant stock increase. The company's performance surpassed the broader sector, and it has shown strong gains over the past month, reflecting resilience in a fluctuating market environment.

Strides Pharma Science's stock has declined for two consecutive days, resulting in a total drop of 7.61%. Despite this recent downturn, the stock has gained 6.06% over the past month, outperforming the broader market. Its technical indicators show a mixed performance relative to various moving averages.

Strides Pharma Science's stock has declined for two consecutive days, resulting in a total drop of 7.61%. Despite this recent downturn, the stock has gained 6.06% over the past month, outperforming the broader market. Its technical indicators show a mixed performance relative to various moving averages.

Strides Pharma Science's stock has declined for two consecutive days, resulting in a total drop of 7.61%. Despite this recent downturn, the stock has gained 6.06% over the past month, outperforming the broader market. Its technical indicators show a mixed performance relative to various moving averages.

Strides Pharma Science has experienced notable stock activity, outperforming its sector and achieving consecutive gains over two days. The stock reached an intraday high and is trading above multiple moving averages, reflecting a strong price trend. In contrast, the broader market, represented by the Sensex, has seen a slight decline.

Strides Pharma Science experienced a notable stock performance on February 4, 2025, reversing a two-day decline with a significant intraday high. The company has outperformed its sector and is trading above multiple moving averages, indicating positive momentum and resilience in the pharmaceuticals industry.

Strides Pharma Science experienced a notable stock performance on February 4, 2025, reversing a two-day decline with a significant intraday high. The company has outperformed its sector and is trading above multiple moving averages, indicating positive momentum and resilience in the pharmaceuticals industry.

Strides Pharma Science experienced notable stock market activity on January 31, 2025, with a significant increase and strong upward momentum over the past three days. The stock outperformed its sector and the broader market, reflecting a solid position within the pharmaceuticals and drugs industry.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.

Strides Pharma Science has announced strong financial results for Q3 FY24-25, with significant year-on-year growth in key metrics. Profit Before Tax reached Rs 110.66 crore, while Profit After Tax was Rs 89.87 crore. The company also improved its debt-equity ratio and inventory turnover, reflecting enhanced operational efficiency.